PACT Pharma
Our Programs

Immuno-Oncology

PACT is currently advancing neoTCR-T cell therapies for patients with different types of solid cancers across the range of low to high tumor mutational burdens. Our pipeline of cancer therapies includes investigational therapies and next generation technologies that have the potential to accelerate curative cell therapies for cancer.

We are currently enrolling patients in our lead Phase 1a/b clinical trial NeoTCR-P1 T cell therapy across eight different tumor types.